AZN
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +16.1% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | 0 | 6.13M | $989.29M | n/a | n/a |
| Q2 2026 | 156 | +6 | 601.40M | $113.10B | +11 | −4 |
| Q1 2026 | 151 | +2 | 571.10M | $111.81B | +21 | −20 |
| Q4 2025 | 148 | 0 | 438.95M | $40.35B | +2 | −1 |
| Q3 2025 | 24 | 0 | 219.30M | $16.82B | +1 | −2 |
| Q2 2025 | 22 | -1 | 189.68M | $13.26B | n/a | −1 |
| Q1 2025 | 21 | 0 | 171.06M | $12.57B | n/a | n/a |
| Q4 2024 | 21 | +3 | 174.28M | $11.42B | +3 | n/a |
| Q3 2024 | 17 | -3 | 166.39M | $12.97B | n/a | −3 |
| Q2 2024 | 20 | n/a | 172.48M | $13.45B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Parnassus Investments, Llc | 2.76M | +339.4% | $446.44M | 1.3% | ▲ Add | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 2.66M | -1.6% | $429.83M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 3 | Ninety One UK Ltd | 290.21K | -80.9% | $47.34M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 4 | Assetmark, Inc | 175.26K | -9.1% | $28.30M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | TD Waterhouse Canada Inc. | 139.63K | +1.5% | $22.19M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | Wealth Enhancement Advisory… | 99.71K | +2.0% | $15.19M | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,307 holders, 729.50M shares, $139.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · See Remarks · 20 sh @ 160.57 · $3,249
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology